RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Stock Information for Redhill Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Redhill Biopharma Ltd.

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
RedHill Biopharma Receives Nasdaq Staff Determination Notification
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.